AR111570A1 - Composición farmacéutica que comprende selexipag - Google Patents

Composición farmacéutica que comprende selexipag

Info

Publication number
AR111570A1
AR111570A1 ARP180100522A ARP180100522A AR111570A1 AR 111570 A1 AR111570 A1 AR 111570A1 AR P180100522 A ARP180100522 A AR P180100522A AR P180100522 A ARP180100522 A AR P180100522A AR 111570 A1 AR111570 A1 AR 111570A1
Authority
AR
Argentina
Prior art keywords
aqueous
pharmaceutical composition
compositions
selexipag
mmol
Prior art date
Application number
ARP180100522A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR111570A1 publication Critical patent/AR111570A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Con composiciones farmacéuticas liofilizadas preparadas a partir de dichas composiciones acuosas, y con composiciones acuosas reconstituidas de estas que son adecuadas para administración i.v. Además se relaciona con procesos para la preparación de dichas composiciones, y con su uso para el tratamiento de enfermedades y trastornos relacionados con el receptor IP. Reivindicación 1: Una composición farmacéutica acuosa que comprende: aproximadamente 0,1 g/kg a 1 g/kg del compuesto 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(metilsulfonil)acetamida de fórmula (1); aproximadamente 2,5% p/p a 10% p/p de un agente de carga que es glicina; aproximadamente 0,05% p/p a 0,4% p/p de un detergente que es polisorbato 20; y un tampón de fosfato acuoso, donde la cantidad total de dicho tampón de fosfato es aproximadamente 5 mmol/kg a 20 mmol/kg; donde el pH de dicha composición farmacéutica acuosa es entre aproximadamente 7 y 8.
ARP180100522A 2017-03-08 2018-03-07 Composición farmacéutica que comprende selexipag AR111570A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08

Publications (1)

Publication Number Publication Date
AR111570A1 true AR111570A1 (es) 2019-07-31

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100522A AR111570A1 (es) 2017-03-08 2018-03-07 Composición farmacéutica que comprende selexipag

Country Status (27)

Country Link
US (1) US20200129506A1 (es)
EP (1) EP3592391B1 (es)
JP (1) JP6964679B2 (es)
KR (1) KR102593075B1 (es)
CN (1) CN110430900B (es)
AR (1) AR111570A1 (es)
AU (1) AU2018229750B2 (es)
BR (1) BR112019018420A2 (es)
CA (1) CA3055010A1 (es)
CL (1) CL2019002511A1 (es)
CO (1) CO2019009221A2 (es)
CR (1) CR20190455A (es)
DO (1) DOP2019000250A (es)
EA (1) EA201992074A1 (es)
EC (1) ECSP19072294A (es)
ES (1) ES2880009T3 (es)
IL (1) IL269061A (es)
JO (1) JOP20190204A1 (es)
MA (1) MA47816A (es)
MX (1) MX2019010598A (es)
NI (1) NI201900090A (es)
PE (1) PE20191492A1 (es)
PH (1) PH12019502033A1 (es)
PL (1) PL3592391T3 (es)
SG (1) SG11201907804QA (es)
TW (1) TWI764996B (es)
WO (1) WO2018162527A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965767A1 (en) * 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
JP2022536623A (ja) * 2019-06-11 2022-08-18 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療方法
IL292354A (en) * 2019-10-23 2022-06-01 Actelion Pharmaceuticals Ltd A pharmaceutical preparation containing Selexifag
JP2023512273A (ja) 2020-01-31 2023-03-24 アクテリオン ファーマシューティカルズ リミテッド 制御放出セレキシパグ組成物
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022215045A1 (en) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Lyophilized composition comprising selexipag
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023209731A1 (en) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
TW202404594A (zh) * 2022-06-10 2024-02-01 日商日本新藥股份有限公司 醫藥組合物
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DK1478339T3 (da) * 2002-02-22 2008-08-25 Schering Corp Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
PT2292231E (pt) 2008-06-23 2015-12-31 Nippon Shinyaku Co Ltd Agente terapêutico para a estenose do canal espinal
DK2289518T3 (en) 2008-06-23 2017-01-16 Nippon Shinyaku Co Ltd Therapeutic agent for inflammatory bowel diseases
PT2447254T (pt) * 2009-06-26 2018-01-04 Nippon Shinyaku Co Ltd Cristais
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
BR112013027009A2 (pt) * 2011-04-19 2016-12-27 Rigshospitalet prostaciclina e análogos da mesa administrada durante cirurgia para prevenção e tratamento de derrame capilar
KR20140082649A (ko) 2011-08-12 2014-07-02 아센디스 파마 에이에스 프로스타사이클린의 서방형 조성물
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
EP3043774B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (en) 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag

Also Published As

Publication number Publication date
ES2880009T3 (es) 2021-11-23
IL269061A (en) 2019-11-28
BR112019018420A2 (pt) 2020-04-14
AU2018229750A1 (en) 2019-09-12
CR20190455A (es) 2019-11-12
JP2020509070A (ja) 2020-03-26
CO2019009221A2 (es) 2019-08-30
US20200129506A1 (en) 2020-04-30
NI201900090A (es) 2020-03-11
DOP2019000250A (es) 2020-09-15
MA47816A (fr) 2020-01-15
CL2019002511A1 (es) 2020-01-17
CN110430900A (zh) 2019-11-08
EP3592391A1 (en) 2020-01-15
SG11201907804QA (en) 2019-09-27
PE20191492A1 (es) 2019-10-21
AU2018229750B2 (en) 2023-11-23
WO2018162527A1 (en) 2018-09-13
JOP20190204A1 (ar) 2019-09-05
JP6964679B2 (ja) 2021-11-10
ECSP19072294A (es) 2019-11-30
KR20190122803A (ko) 2019-10-30
MX2019010598A (es) 2019-10-15
EA201992074A1 (ru) 2020-02-27
EP3592391B1 (en) 2021-04-21
CN110430900B (zh) 2023-09-19
PH12019502033A1 (en) 2020-06-15
CA3055010A1 (en) 2018-09-13
TWI764996B (zh) 2022-05-21
PL3592391T3 (pl) 2021-11-02
TW201842910A (zh) 2018-12-16
KR102593075B1 (ko) 2023-10-23

Similar Documents

Publication Publication Date Title
AR111570A1 (es) Composición farmacéutica que comprende selexipag
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
CL2018003178A1 (es) Composición farmacéutica
UY37971A (es) Derivados de indol macrocíclicos sustituidos
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
EA202090536A1 (ru) Кристаллические формы 3-замещенного 1,2,4-оксадиазола
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
EA201992328A1 (ru) Фармацевтическая композиция, содержащая ленватиниба мезилат
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
BR112017019431A2 (pt) material de implante de compósito
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
PH12017501736A1 (en) Indole derivatives
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
BR112019022918A2 (pt) Agentes farmacêuticos, composições e métodos relativos aos mesmos

Legal Events

Date Code Title Description
FB Suspension of granting procedure